ERYTHROPOIETIN STUDY

Phase 1

Recruiting

• Conditions: Acute Myocardial Infarction (AMI); Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12606000238572
• Lead Sponsor: Eastern Heart Clinic

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-06-14
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Acute ST elevation myocardial infarction that are treated with primary angioplasty and stenting who have significant left ventricular (LV) impairment.

Exclusion Criteria

Multiple - but particularly major comorbidities.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. all cause mortality[At 6 months];2. hyperviscosity events (stent thrombosis, stroke, AMI or heart failure in the setting of a concomitant high haematocrit)[At 6 months]

Secondary Outcome Measures

Name	Time	Method
1. Left ventricular ejection fraction[At 6 months];2. Readmission for cardiac failure [Over 6 months];3. Target vessel revascularisation [Over 6 months];4. Change in New York Heart Association functional class [Over 6 months (assessed at baseline, 30, 90 and 180 days).]